Kuvatris Therapeutics Inc's Comment on Sales, Marketing and Customers
The company plans to market and sell its products either by developing its own sales, marketing, and distribution infrastructure or through collaborations with third parties. In the U.S. market, it intends to establish its own sales organization only when product candidates reach Phase 3 clinical trials or are nearing New Drug Application (NDA) submission, and shortly before FDA approval of PAX-101 or other neurologic indication products. The company does not plan to create a sales organization for PAX-101 as a treatment for East African Human African Trypanosomiasis (HAT).
In June 2023, the company entered into an exclusive specialty benefit manager agreement with Vox Nova, LLC, designating Vox Nova as the exclusive U.S. distributor for PAX-101 for up to seven years. Vox Nova will provide distribution management, pharmacy benefit management, sales, and supply monitoring services upon FDA approval.
The pharmaceutical industry is highly competitive, with competitors including commercial pharmaceutical and biotechnology companies, academic institutions, government agencies, and research institutions, some of which may have more advanced products or greater resources. For PAX-101 in Autism Spectrum Disorder (ASD), where no known cure or FDA-approved medication for core symptoms exists, competitors developing drugs include CureMark LLC (Phase 3 for CM-AT), Yamo Pharmaceuticals (Phase 2 for LI-79), GW Pharmaceuticals (Phase 2 for Cannabidivarin), Harmony Biosciences (Phase 3 for CBD gel), and QBioMed (preclinical QBM-001 for rare pediatric conditions).
New York-based biopharmaceutical company, PaxMedica, Inc. (OTC:PXMD), is currently facing a delisting threat by Nasdaq. In response, PaxMedica has taken swift action by filing an appeal with the Nasdaq Office of Appeals and Review. The company also announced its preparations for an upcoming meeting with the U.S. Food and Drug Administration (FDA) regarding its innovative drug, PAX-101. This article aims to provide an overview of PaxMedica s current situation, recent achievements, and potential implications for the company.Nasdaq Delisting Appeal:Upon receiving the delisting notification from Nasdaq on April 30th, PaxMedica made the decision to formally appeal the decision. The company believes that the Nasd...
Kuvatris Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company plans to market and sell its products either by developing its own sales, marketing, and distribution infrastructure or through collaborations with third parties. In the U.S. market, it intends to establish its own sales organization only when product candidates reach Phase 3 clinical trials or are nearing New Drug Application (NDA) submission, and shortly before FDA approval of PAX-101 or other neurologic indication products. The company does not plan to create a sales organization for PAX-101 as a treatment for East African Human African Trypanosomiasis (HAT).
In June 2023, the company entered into an exclusive specialty benefit manager agreement with Vox Nova, LLC, designating Vox Nova as the exclusive U.S. distributor for PAX-101 for up to seven years. Vox Nova will provide distribution management, pharmacy benefit management, sales, and supply monitoring services upon FDA approval.
The pharmaceutical industry is highly competitive, with competitors including commercial pharmaceutical and biotechnology companies, academic institutions, government agencies, and research institutions, some of which may have more advanced products or greater resources. For PAX-101 in Autism Spectrum Disorder (ASD), where no known cure or FDA-approved medication for core symptoms exists, competitors developing drugs include CureMark LLC (Phase 3 for CM-AT), Yamo Pharmaceuticals (Phase 2 for LI-79), GW Pharmaceuticals (Phase 2 for Cannabidivarin), Harmony Biosciences (Phase 3 for CBD gel), and QBioMed (preclinical QBM-001 for rare pediatric conditions).
Sources:
Kuvatris Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Kuvatris Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Kuvatris Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
